253 related articles for article (PubMed ID: 23209571)
1. Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.
Hecht R; Li YS; Sun J; Belouski E; Hall M; Hager T; Yie J; Wang W; Winters D; Smith S; Spahr C; Tam LT; Shen Z; Stanislaus S; Chinookoswong N; Lau Y; Sickmier A; Michaels ML; Boone T; Véniant MM; Xu J
PLoS One; 2012; 7(11):e49345. PubMed ID: 23209571
[TBL] [Abstract][Full Text] [Related]
2. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J
Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011
[TBL] [Abstract][Full Text] [Related]
3. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.
Pan Q; Lin S; Li Y; Liu L; Li X; Gao X; Yan J; Gu B; Chen X; Li W; Tang X; Chen C; Guo L
EBioMedicine; 2021 Jan; 63():103202. PubMed ID: 33421947
[TBL] [Abstract][Full Text] [Related]
4. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys.
Véniant MM; Komorowski R; Chen P; Stanislaus S; Winters K; Hager T; Zhou L; Wada R; Hecht R; Xu J
Endocrinology; 2012 Sep; 153(9):4192-203. PubMed ID: 22798348
[TBL] [Abstract][Full Text] [Related]
5. A novel approach to improve the function of FGF21.
Smith R; Duguay A; Weiszmann J; Stanislaus S; Belouski E; Cai L; Yie J; Xu J; Gupte J; Wu X; Li Y
BioDrugs; 2013 Apr; 27(2):159-66. PubMed ID: 23456652
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.
Giragossian C; Vage C; Li J; Pelletier K; Piché-Nicholas N; Rajadhyaksha M; Liras J; Logan A; Calle RA; Weng Y
Drug Metab Dispos; 2015 Jun; 43(6):803-11. PubMed ID: 25805881
[TBL] [Abstract][Full Text] [Related]
7. [Expression and pharmacological evaluation of fusion protein FGF21-L-Fc].
Yao WB; Ren GP; Han Y; Cao HW; Gao HM; Kan FM; Wang Q; Li DS
Yao Xue Xue Bao; 2011 Jul; 46(7):787-92. PubMed ID: 22010347
[TBL] [Abstract][Full Text] [Related]
8. [Optimization and characterization of a novel FGF21 mutant].
Ye XL; Gao HS; Wang WF; Ren GP; Liu MY; He K; Zhang YK; Zhao JZ; Yu D; Li DS
Yao Xue Xue Bao; 2012 Jul; 47(7):897-903. PubMed ID: 22993854
[TBL] [Abstract][Full Text] [Related]
9. Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.
Weng Y; Ishino T; Sievers A; Talukdar S; Chabot JR; Tam A; Duan W; Kerns K; Sousa E; He T; Logan A; Lee D; Li D; Zhou Y; Bernardo B; Joyce A; Kavosi M; O'Hara DM; Clark T; Guo J; Giragossian C; Stahl M; Calle RA; Kriz R; Somers W; Lin L
Sci Rep; 2018 Mar; 8(1):4241. PubMed ID: 29523796
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
11. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Glaesner W; Vick AM; Millican R; Ellis B; Tschang SH; Tian Y; Bokvist K; Brenner M; Koester A; Porksen N; Etgen G; Bumol T
Diabetes Metab Res Rev; 2010 May; 26(4):287-96. PubMed ID: 20503261
[TBL] [Abstract][Full Text] [Related]
12. Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases.
Zhao L; Niu J; Lin H; Zhao J; Liu Y; Song Z; Xiang C; Wang X; Yang Y; Li X; Mohammadi M; Huang Z
EBioMedicine; 2019 Oct; 48():462-477. PubMed ID: 31631034
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
14. FGF21 acts as a negative regulator of bile acid synthesis.
Chen MM; Hale C; Stanislaus S; Xu J; Véniant MM
J Endocrinol; 2018 May; 237(2):139-152. PubMed ID: 29615519
[TBL] [Abstract][Full Text] [Related]
15. Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action.
Gilroy CA; Roberts S; Chilkoti A
J Control Release; 2018 May; 277():154-164. PubMed ID: 29551712
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.
Zarei M; Pujol E; Quesada-López T; Villarroya F; Barroso E; Vázquez S; Pizarro-Delgado J; Palomer X; Vázquez-Carrera M
Br J Pharmacol; 2019 Jul; 176(13):2292-2305. PubMed ID: 30927369
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody.
Huang J; Ishino T; Chen G; Rolzin P; Osothprarop TF; Retting K; Li L; Jin P; Matin MJ; Huyghe B; Talukdar S; Bradshaw CW; Palanki M; Violand BN; Woodnutt G; Lappe RW; Ogilvie K; Levin N
J Pharmacol Exp Ther; 2013 Aug; 346(2):270-80. PubMed ID: 23720456
[TBL] [Abstract][Full Text] [Related]
18. Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics.
Li S; Song Z; Fan C; Zhang W; Ma T; Li X; Zhang Q; Zhao M; Yu T; Li S
Biochem Pharmacol; 2024 Jul; 225():116306. PubMed ID: 38782076
[TBL] [Abstract][Full Text] [Related]
19. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
So WY; Leung PS
Med Res Rev; 2016 Jul; 36(4):672-704. PubMed ID: 27031294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
